Results 131 to 140 of about 5,080 (193)

Label-Free Detection of Cellular Aβ Accumulation and Mitochondrial Dysfunction in AD Cell Models via Raman Microscopy. [PDF]

Anal Chem
Mitsuoka Y, Morimoto T, Bando K, Hara S, Fujita K, Nishida K.   +5 more
europepmc   +1 more source

Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies. [PDF]

eNeuro
McDiarmid A.
europepmc   +1 more source

Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. [PDF]

Alzheimers Dement
Grenon MB, Cline EN, Jerecic J, Johnson E, Siemers E, Lemere CA.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Donanemab and Lecanemab Over a Lifetime Horizon for Patients with Early Alzheimers Disease

Background: Donanemab was recently approved following the 2023 approval of lecanemab for early Alzheimers disease (AD). While both therapies represent important advances in disease-modifying treatments, substantial concerns remain regarding their ...
Wu, Jun, Lv, Gang, Burroughs, Amber, Jiang, Xiangxiang, Yuan, Jing, Lu, Kevin   +5 more
core  

CellSwarm-AD: A Multi-Scale Agent-Based Framework for Virtual Alzheimer's Disease Trials. [PDF]

Int J Mol Sci
Tan CL, Zheng XM, Zhu YF, Xiong QQ, Li H, Meng XL.   +5 more
europepmc   +1 more source

Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community. [PDF]

Neurol Sci
Santos DH, da Silva AMP.
europepmc   +1 more source

Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series. [PDF]

Front Psychiatry
Han J, Fang Y, Esiaka D, Abraham O.
europepmc   +1 more source

Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment. [PDF]

Alzheimers Dement
Kang SH, Park YJ, Lee S, Kang J, Lee S, Lee ES, Jung HN, Ryoo I, Hwang H, Choi K, Eo JS, Suh SI, Oh K, Koh SB.   +13 more
europepmc   +1 more source

Amyloid-related imaging abnormalities after immunotherapy: How might brain microvascular basement membrane components be involved? [PDF]

J Alzheimers Dis
Vinters HV, Magaki S.
europepmc   +1 more source

Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions. [PDF]

Front Neurol
Zupan M, Prelog PR, Kramberger MG, Frol S.   +3 more
europepmc   +1 more source